The risk of malignancy in patients with RA treated with JAKi versus TNFi
| Type of targeted therapy | Number of patients | Number of events | Total observation periods (person-year) | IR (95% CI) | HR (95% CI) | |
| Before IPTW | ||||||
| Overall malignancy | JAKi | 1064 | 7 | 1288.6 | 0.54 (0.26 to 1.14) | 0.69 (0.30 to 1.56) |
| TNFi | 3865 | 58 | 6823.8 | 0.85 (0.66 to 1.10) | ||
| Solid malignancy | JAKi | 1064 | 6 | 1288.6 | 0.47 (0.21 to 1.04) | 0.61 (0.26 to 1.47) |
| TNFi | 3865 | 56 | 6823.8 | 0.82 (0.63 to 1.07) | ||
| Haematological malignancy | JAKi | 1064 | 1 | 1288.6 | 0.08 (0.01 to 0.55) | 2.41 (0.15 to 37.99) |
| TNFi | 3865 | 2 | 6823.8 | 0.03 (0.01 to 0.12) | ||
| After IPTW | ||||||
| Overall malignancy | JAKi | 4101 | 34 | 4985.3 | 0.67 (0.48 to 0.94) | 0.83 (0.55 to 1.27) |
| TNFi | 5131 | 72 | 8457.1 | 0.85 (0.67 to 1.07) | ||
| Solid malignancy | JAKi | 4101 | 30 | 4985.3 | 0.61 (0.43 to 0.87) | 0.77 (0.50 to 1.19) |
| TNFi | 5131 | 70 | 8457.1 | 0.82 (0.65 to 1.04) | ||
| Haematological malignancy | JAKi | 4101 | 3 | 4985.3 | 0.06 (0.02 to 0.19) | 2.86 (0.41 to 20.00) |
| TNFi | 5131 | 2 | 8457.1 | 0.02 (0.01 to 0.10) | ||
Incidence rate per 100 person-years was calculated.
IPTW, inverse probability of treatment weighting; IR, incidence rate; JAKi, Janus kinase inhibitor; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor.